Primary-source record

MaterialTrial registry change

Aptevo refines mipletamig priming-dose regimen, substantially reducing IRRs in frontline AML

Aptevo announced refinements to the priming-dose regimen for mipletamig in the ongoing RAINIER Phase 1b/2 study substantially reduced the frequency and severity of infusion-related reactions. This improves tolerability without compromising planned therapeutic dosing and advances preparation for Phase 2 development and regulatory discussions with the FDA. The company expects to complete the current study by year-end 2026 and initiate Phase 2 in 2027.

Key facts

Filed
Nov 5, 2026, 01:35 PM
Event
Trial registry change
Direction
Positive
Source
SEC 8-K
Confidence
Sourced

Source excerpt

EX-99.1 2 apvo-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Aptevo Achieves Key Clinical Development Objective, Significantly Reducing Infusion-Related Reactions with Mipletamig in Frontline AML Refined priming-dose regimen addresses important treatment-tolerability objective identified through FDA discussions, further strengthening mipletamig's readiness for Phase 2 development Substantial reduction in infusion reaction frequency and severity improves the patient treatment experience without compromising planned therapeutic dosing Achievement builds on mipletamig's encouraging clinical activity and favorable safety profile as a potential addition to the current standard of care SEATTLE, WA, November 5, 2026 — Aptevo Therapeutics Inc. (NASDAQ: APVO), a clinical-stage biotechnology company developing novel multispecific immuno-oncology therapeutics, today announced an important clinical development milestone for mipletamig: a substantial reduction in infusion-related reactions (IRRs) following successive refinements to its priming-dose regimen. The improvement builds on mipletamig's already favorable safety and tolerability profile, including encouraging cytokine release syndrome (CRS) findings observed throughout its clinical development. Mipletamig data will be presented at the American Society of Hematology (ASH) 68 th Annual Meeting in New Orleans, Louisiana from December 12-15, 2026. The ongoing RAINIER dose optimization study has demonstrated encouraging clinical activity

SEC 8-K

More on this asset

Oct 26, 2026
12:13 PM
APVOAptevo Therapeutics Inc

Aptevo: 21% of frontline AML patients on mipletamig + VEN+AZA advanced to stem cell transplant

Trial registry changeSEC 8-K
Aptevo refines mipletamig priming-dose regimen, substantially reducing IRRs in frontline AML | SimianX AI